Pesquisar
Denali Therapeutics Inc
DNLIAdicionar à lista de desejos
19.210USD
-0.590-2.98%
Horário de mercado （ET）Cotações atrasadas em 15 min
3.05BValor de mercado
PerdaP/L TTM
Mais detalhes de Denali Therapeutics Inc Empresa
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
Informações de Denali Therapeutics Inc
Código da empresaDNLI
Nome da EmpresaDenali Therapeutics Inc
Data de listagemDec 08, 2017
CEOWatts (Ryan J)
Número de funcionários422
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 08
Endereço161 Oyster Point Blvd.
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Telefone16508668547
Sitehttps://www.denalitherapeutics.com
Código da empresaDNLI
Data de listagemDec 08, 2017
CEOWatts (Ryan J)
Executivos da empresa Denali Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.45M
-2.04%
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
806.58K
+0.12%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
--
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
--
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
--
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
26.07K
--
Dr. Marc Tessier-Lavignec, Ph.D.
Dr. Marc Tessier-Lavignec, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven E. (Steve) Krognes
Mr. Steven E. (Steve) Krognes
Director
Director
--
--
Ms. Nancy A. Thornberry
Ms. Nancy A. Thornberry
Independent Director
Independent Director
--
--
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.45M
-2.04%
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
806.58K
+0.12%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
--
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
--
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
--
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
26.07K
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: dom, 10 de mai
Atualizado em: dom, 10 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Baillie Gifford & Co.
7.60%
BlackRock Institutional Trust Company, N.A.
6.56%
T. Rowe Price Investment Management, Inc.
4.57%
Biogen Inc
4.51%
Temasek Holdings Pte. Ltd.
4.42%
Outro
72.34%
Investidores
Investidores
Proporção
Baillie Gifford & Co.
7.60%
BlackRock Institutional Trust Company, N.A.
6.56%
T. Rowe Price Investment Management, Inc.
4.57%
Biogen Inc
4.51%
Temasek Holdings Pte. Ltd.
4.42%
Outro
72.34%
Tipos de investidores
Investidores
Proporção
Investment Advisor
52.46%
Investment Advisor/Hedge Fund
21.59%
Hedge Fund
14.03%
Sovereign Wealth Fund
7.64%
Individual Investor
4.62%
Corporation
4.51%
Research Firm
2.29%
Bank and Trust
1.11%
Private Equity
0.63%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
555
158.73M
100.01%
+922.46K
2025Q4
520
148.33M
104.72%
+27.93K
2025Q3
534
148.30M
106.07%
+2.76M
2025Q2
533
144.90M
104.92%
+4.11M
2025Q1
521
140.91M
100.82%
-5.51M
2024Q4
508
135.26M
104.03%
-2.70M
2024Q3
500
139.34M
103.43%
+2.39M
2024Q2
486
129.82M
93.98%
+2.48M
2024Q1
475
127.09M
84.98%
+6.07M
2023Q4
485
116.85M
84.85%
+2.16M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Baillie Gifford & Co.
12.31M
7.76%
+719.30K
+6.21%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
10.41M
6.56%
+283.36K
+2.80%
Dec 31, 2025
T. Rowe Price Investment Management, Inc.
7.25M
4.57%
+1.62M
+28.65%
Dec 31, 2025
Biogen Inc
7.16M
4.51%
-5.60M
-43.89%
Oct 30, 2024
Temasek Holdings Pte. Ltd.
7.01M
4.42%
+1.66M
+30.94%
Dec 31, 2025
State Street Investment Management (US)
6.26M
3.95%
+799.11K
+14.62%
Dec 31, 2025
Norges Bank Investment Management (NBIM)
5.12M
3.23%
+1.17M
+29.70%
Dec 31, 2025
Fidelity Management & Research Company LLC
4.79M
3.02%
-223.13K
-4.45%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Neuroscience and Healthcare ETF
4.13%
Global X Guru Index ETF
1.33%
ALPS Medical Breakthroughs ETF
0.98%
Virtus LifeSci Biotech Clinical Trials ETF
0.74%
State Street SPDR S&P Biotech ETF
0.73%
Direxion Daily S&P Biotech Bull 3X Shares
0.45%
Global X Aging Population ETF
0.38%
ProShares Ultra Nasdaq Biotechnology
0.35%
iShares Health Innovation Active ETF
0.35%
Invesco Nasdaq Biotechnology ETF
0.23%
Ver Mais
iShares Neuroscience and Healthcare ETF
Proporção4.13%
Global X Guru Index ETF
Proporção1.33%
ALPS Medical Breakthroughs ETF
Proporção0.98%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.74%
State Street SPDR S&P Biotech ETF
Proporção0.73%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.45%
Global X Aging Population ETF
Proporção0.38%
ProShares Ultra Nasdaq Biotechnology
Proporção0.35%
iShares Health Innovation Active ETF
Proporção0.35%
Invesco Nasdaq Biotechnology ETF
Proporção0.23%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
